Like The Herald Business Journal on Facebook!
The Herald of Everett, Washington
Heraldnet.com

The top local business stories in your email

Contact Us:

Josh O'Connor
Publisher
Phone: 425-339-3007
joconnor@heraldnet.com

Jody Knoblich
General Sales Manager
Phone: 425-339-3445
Fax: 425-339-3049
jknoblich@heraldnet.com

Jim Davis
Editor
Phone: 425-339-3097
jdavis@heraldnet.com

Site address:
1800 41st Street, S-300,
Everett, WA 98203

Mailing address:
P.O. Box 930
Everett, WA 98206

HBJ RSS feeds

Watson’s medical expertise offered commercially

IBM's former "Jeopardy" champ will use its supercomputing skills to help doctors diagnose disease and health insurance companies manage claims.

SHARE: facebook Twitter icon Pinterest icon Linkedin icon Google+ icon Email icon |  PRINTER-FRIENDLY  |  COMMENTS
By Jim Fitzgerald
Associated Press
Published:
  • "Jeopardy!" champions Ken Jennings (left) and Brad Rutter (right) flank a prop representing the supercomputer Watson during a practice round...

    Associated Press file photo, 2011

    "Jeopardy!" champions Ken Jennings (left) and Brad Rutter (right) flank a prop representing the supercomputer Watson during a practice round of the "Jeopardy!" quiz show in Yorktown Heights, N.Y. on Jan. 13, 2011.

WHITE PLAINS, N.Y. -- Dr. Watson is accepting new patients.
The Watson supercomputer is graduating from its medical residency and is being offered commercially to doctors and health insurance companies, IBM said Friday.
IBM Corp., the health insurer WellPoint Inc. and Memorial Sloan-Kettering Cancer Center announced two Watson-based applications -- one to help diagnose and treat lung cancer and one to help manage health insurance decisions and claims.
Both applications take advantage of the speed, huge database and language skill the computer demonstrated in defeating the best human "Jeopardy!" players on television two years ago.
Armonk-based IBM said Watson has improved its performance by 240 percent since the "Jeopardy!" win.
In both applications, doctors or insurance company workers will reach Watson through a tablet or computer. Watson will quickly compare a patient's medical records to what it has learned and make several recommendations in decreasing order of confidence.
In the cancer program, the computer will be considering what treatment is most likely to succeed. In the insurance program, it will consider what treatment should be authorized for payment.
Watson (actually named for IBM founder and not the Sherlock Holmes' friend, Dr. Watson) has been trained in medicine through pilot programs at Indianapolis-based WellPoint and at Sloan-Kettering in New York.
Manoj Saxena, an IBM general manager, said the supercomputer has ingested 1,500 lung cancer cases from Sloan-Kettering records, plus 2 million pages of text from journals, textbooks and treatment guidelines.
It also learned "like a medical student," by being corrected when it was questioned by doctors and came up with wrong answers, Saxena said in an interview.
"Watson is not making the decisions" on treatment or authorization, Saxena said. "It is essentially reducing the effort for doctors and nurses by going through thousands of pages of information for each case."
The lung cancer program is being adopted by two medical groups, the Maine Center for Cancer Medicine and WestMed in New York's Westchester County. Saxena said it should be running at both groups by next month.
WellPoint itself is already using the insurance application in Indiana, Kentucky, Ohio and Wisconsin. It will be selling both applications -- at prices still to be negotiated -- and will compensate IBM under a contract between the two companies, an IBM spokeswoman said.
WellPoint said using Watson should not increase insurance premiums because of savings from waste and errors
Story tags » HardwareInternet & CloudHealth treatmentHuman SciencesTechnology (general)

Related

MORE HBJ HEADLINES

CALENDAR

Share your comments: Log in using your HeraldNet account or your Facebook, Twitter or Disqus profile. Comments that violate the rules are subject to removal. Please see our terms of use. Please note that you must verify your email address for your comments to appear.

You are logged in using your HeraldNet ID. Click here to update your profile. | Log out.

Our new comment system is not supported in IE 7. Please upgrade your browser here.

comments powered by Disqus